0 338

Cited 0 times in

Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy.

Authors
 Hye Ryun Kim  ;  Jee Hung Kim  ;  Yumie Rhee  ;  Hosun Lee  ;  Seung Eun Song  ;  Chan Kim  ;  Sukyung Song  ;  Sung Hoon Noh  ;  Sun Young Rha 
Citation
 ONCOLOGY, Vol.90(5) : 248-254, 2016 
Journal Title
 ONCOLOGY 
ISSN
 0030-2414 
Issue Date
2016
MeSH
Adrenal Glands/drug effects* ; Adrenal Glands/metabolism* ; Adrenal Insufficiency/blood* ; Adrenal Insufficiency/chemically induced* ; Adrenal Insufficiency/physiopathology ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects* ; Biomarkers/blood ; Chemotherapy, Adjuvant ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Disease-Free Survival ; Drug Combinations ; Female ; Gastrectomy ; Health Status ; Humans ; Hydrocortisone/blood ; Incidence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Pilot Projects ; Prospective Studies ; Quality of Life* ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/physiopathology ; Tegafur/administration & dosage ; Tegafur/adverse effects ; Treatment Outcome
Keywords
Chemotherapy ; Quality of life ; Adrenal insufficiency ; Advanced gastric cancer
Abstract
OBJECTIVE: We performed this prospective study to identify both the incidence of adrenal insufficiency (AI) and health-related quality of life (HRQOL) in advanced gastric cancer (AGC) patients who were treated with the S-1 plus cisplatin (SP) regimen as a first-line palliative chemotherapy. METHODS: We assessed adverse events (AEs) observed in 52 patients who received the SP regimen for AGC between January 2009 and June 2010 using the Common Toxicity Criteria Adverse Events (CTCAE) version 3.0. Adrenal function was assessed at baseline and 12 weeks after chemotherapy using the low-dose adrenocorticotropic hormone stimulation test. HRQOL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC-QLQ C30). RESULTS: The incidence of AI was 30.8% (n = 16) and of AE observed 55% (n = 29) among 52 patients after 12 weeks of chemotherapy. Of 29 patients with AE, 34.4% (n = 10) were diagnosed with AI, and of 23 patients without AE, 26.1% (n = 6) were diagnosed with AI. CONCLUSION: The incidence of secondary AI in AGC patients was not rare and was not correlated with the presence of nonspecific AEs. Although patients diagnosed with AI did not show any related symptoms, they are at risk of potentially life-threatening consequences. Thus, the evaluation of AI could be suggested for patients who received chemotherapy.
Full Text
http://www.karger.com/Article/FullText/445010
DOI
10.1159/000445010
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jee Hung(김지형) ORCID logo https://orcid.org/0000-0002-9044-8540
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Song Su Kyung(송수경)
Song, Seung Eun(송승은)
Rhee, Yumie(이유미) ORCID logo https://orcid.org/0000-0003-4227-5638
Lee, Ho Sun(이호선)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/146869
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links